Fin Trust Capital Advisors, LLC Zentalis Pharmaceuticals, Inc. Transaction History
Fin Trust Capital Advisors, LLC
- $510 Million
- Q1 2024
A detailed history of Fin Trust Capital Advisors, LLC transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Fin Trust Capital Advisors, LLC holds 17 shares of ZNTL stock, worth $69. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17
Previous 17
-0.0%
Holding current value
$69
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding ZNTL
# of Institutions
142Shares Held
76.3MCall Options Held
68.2KPut Options Held
2.3K-
Matrix Capital Management Company, LP Waltham, MA14MShares$57.1 Million2.04% of portfolio
-
Eventide Asset Management, LLC Boston, MA11.6MShares$47.3 Million2.94% of portfolio
-
Black Rock Inc. New York, NY4.65MShares$19 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.4MShares$18 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il3.85MShares$15.8 Million0.01% of portfolio
About Zentalis Pharmaceuticals, Inc.
- Ticker ZNTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,983,600
- Market Cap $233M
- Description
- Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...